DJIA 17,156.85 24.88 0.15%
NASDAQ 4,562.19 9.43 0.21%
S&P 500 2,001.57 2.59 0.13%
market minute promo

Exelixis (NASDAQ: EXEL)

1.70 0.08 (4.94%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

EXEL $1.70 4.94%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.63
Previous Close $1.62
Daily Range $1.62 - $1.72
52-Week Range $1.60 - $8.41
Market Cap $331.7M
P/E Ratio -1.07
Dividend (Yield) $0.00 (0.0%)
Volume 3,012,555
Average Daily Volume 4,698,018
Current FY EPS -$1.43





Exelixis (EXEL) Description

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. Website:

News & Commentary Rss Feed

Why Exelixis Inc. Stock Crashed By 70% in 2014

Exelixis stock got mauled after its lead drug failed to impress in a key late-stage study. Find out whether there's any hope left for this biotech stock or if it's time for investors to kiss it goodbye.

Anika Therapeutics: A Recent Greenblatt Small Cap Biotech Pick

Stocks Hitting 52-Week Lows

Tokai Pharmaceuticals IPO: Lack Of Product Diversity Should Leave Investors Cautious

Exelixis' (EXEL) CEO Michael Morrissey Presents at Morgan Stanley Healthcare Conference (Transcript)

Weekly 3-Year Low Highlights: UAN, CLD, EXEL, QNST

Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte

Exelixis Slumps 55% on Disappointing Cabozantinib Results - Analyst Blog

Exelixis (EXEL) Enters Oversold Territory - Tale of the Tape

Update: Exelixis COMET-1 Trial Fails: The Impact To My Bull Thesis

See More EXEL News...

EXEL's Top Competitors

EXEL $1.70 (4.94%)
Current stock: EXEL
ILMN $177.00 (2.30%)
Current stock: ILMN
TMO $123.60 (0.81%)
Current stock: TMO
WAT $101.57 (0.25%)
Current stock: WAT